Valeant Announces 2018 Annual Meeting Results

LAVAL, Quebec, May 1, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today the election of the ten directors nominated at its 2018 annual meeting of shareholders held on April 30, 2018. The detailed results of the vote for the election of directors are set out below:

At the annual meeting, shareholders also approved the non-binding advisory vote on named executive officer compensation and an amendment to the Company's 2014 Omnibus Incentive Plan to increase the number of common shares authorized under such plan, and appointed PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm until the close of the Company's 2019 annual meeting of shareholders.

The final vote tabulation on all matters voted on at the meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K and such report will be made available on the Company's web site at www.valeant.com.

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.

SOURCE Valeant Pharmaceuticals International, Inc.